While GSK’s fundamental value remains compelling, overhangs for the company’s Arexvy and Shingrix vaccines, “more subdued” 2025 growth, and few near-term catalysts to “rebuild belief” suggests the ...

The U.S. Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines, the company said on Monday.

Good day, ladies and gentlemen, and welcome to the Dynavax Technologies third quarter 2024 financial results conference call.

During a rally appearance in New York City, former President Donald Trump said that if elected, he would let Robert F. Kennedy Jr. "go wild" on public health issues ...

Zero shingles cases after 18.8 months follow-up in 619 patients receiving any dose of amezosvatein, a development-stage adjuvanted subunit ...

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

30, missing market expectations of 238 million pounds, while sales of shingles vaccine, Shingrix, fell 7% to 739 million pounds, also below estimates in a company compiled consensus. Walmsley told ...

“This vaccine is kind of a really nice proof of principle” that the mRNA technology can tackle another major public health threat, he added. C. diff exacts damage on several fronts. It hangs out in ...

GlaxoSmithKline’s shingles vaccine Shingrix has gained the unanimous backing of an FDA advisory committee. The Vaccines and Related Biological Products Advisory Committee vote sets the product ...

In the United States, an estimated 12,000 to 52,000 people die every year from flu-related causes. Hundreds of thousands have been hospitalized from this ever-evolving respiratory infection. Older ...